Streamlining Genetic Testing Denial Appeal Automation

The Challenge of Genetic Testing Denials

The unique nature of genetic testing, from the rapid evolution of diagnostic panels to the interpretation of complex genomic data, often results in prior authorization denials based on medical necessity, coverage criteria, or documentation gaps. Manual appeal processes for these cases consume valuable staff time, delay patient care, and are prone to errors, particularly when navigating the specific requirements of RBMs and individual payer policies for hereditary cancer panels, prenatal testing, and pharmacogenomic assays.

Current Manual Appeal Workflow for Genetic Testing

Without dedicated automation, the process of appealing a denied genetic test prior authorization is labor-intensive. It typically involves staff manually determining appealability, meticulously gathering additional clinical documentation from EMRs (often including detailed genomic reports and family histories), and drafting bespoke appeal letters. Navigating the correct appeal pathway—first-level, second-level, or peer-to-peer—and submitting through varied payer channels (portals, fax, postal mail) further complicates timely resolution and accurate tracking.

Common Failure Modes in Genetic Testing Appeals

• **Documentation Gaps:** Missing specific genetic test results, lab reports, or family history details crucial for demonstrating medical necessity.
• **Incorrect Appeal Level:** Misclassifying a denial, leading to an appeal being sent to the wrong review tier (e.g., first-level vs. second-level).
• **Timely-Filing Breaches:** Missing critical deadlines for appeal submission due to complex documentation requirements and manual tracking.
• **Lost-to-Follow-Up Appeals:** Appeals becoming untracked within the system, resulting in lost revenue.
• **Inconsistent Appeal Letter Quality:** Variability in the persuasiveness and completeness of appeal letters across different prior authorization coordinators.

Klivira's Automated Appeal Workflow for Genetic Testing

Klivira’s platform integrates directly with your EMR to provide end-to-end genetic testing denial appeal automation. Our system classifies denials using normalized CARC/RARC taxonomy to route cases to the appropriate appeal pathway, leveraging a comprehensive payer-policy library for per-payer appeal specifications. Crucially, Klivira uses FHIR-based re-discovery to pull additional clinical documentation—such as updated genetic test results, consult notes, or relevant peer-reviewed literature for off-label indications—that was not included in the original PA submission.

Addressing Genetic Testing Appeal Failures with Automation

Klivira directly mitigates the most common failure modes in genetic testing appeals. Automated FHIR-based documentation re-discovery ensures all relevant genomic data and clinical evidence are included. Payer-policy-aware pathway selection prevents appeals from being sent to the wrong review level. Automated tracking with timely-filing window enforcement and escalation rules eliminates lost-to-follow-up cases. Our system drafts clinician-reviewable appeal letters from payer-specific templates, incorporating relevant clinical guidelines like NCCN for hereditary cancer panels, ensuring consistent quality and evidence-based arguments.

Impact on Revenue Cycle and Operational Efficiency

By automating genetic testing denial appeals, health systems can significantly improve their revenue capture for high-value services. Reduced rework costs, as benchmarked by industry data such as the CAQH Index, contribute directly to a healthier financial bottom line. Furthermore, operational efficiency gains free up prior authorization coordinators to focus on more complex cases, enhancing overall throughput and ensuring patients receive timely access to critical genetic diagnostics.